Zebrafish models for the functional genomics of neurogenetic disorders  by Kabashi, Edor et al.
Biochimica et Biophysica Acta 1812 (2011) 335–345
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbad isReview
Zebraﬁsh models for the functional genomics of neurogenetic disorders☆
Edor Kabashi a,b, Edna Brustein b, Nathalie Champagne a,b, Pierre Drapeau b,⁎
a Center for Excellence in Neuromics, CHUM Research Center and the Department of Medicine, Université de Montréal, Montréal, QC, Canada
b Department of Pathology and Cell Biology and Groupe de recherche sur le système nerveux central, Université de Montréal, Montréal, QC, Canada☆ This article is part of a Special Issue entitled Zeb
Diseases.
⁎ Corresponding author. Department of Pathology a
Montréal, C.P. 6128, Succ. Centre-ville, Montréal, Québec
343 7087; fax: +1 514 343 5755.
E-mail address: p.drapeau@umontreal.ca (P. Drapea
0925-4439/$ – see front matter © 2010 Elsevier B.V. Al
doi:10.1016/j.bbadis.2010.09.011a b s t r a c ta r t i c l e i n f oArticle history:
Received 4 December 2009
Accepted 22 September 2010










Trangenic animalsIn this review, we consider recent work using zebraﬁsh to validate and study the functional consequences of
mutations of human genes implicated in a broad range of degenerative and developmental disorders of the
brain and spinal cord. Also we present technical considerations for those wishing to study their own genes of
interest by taking advantage of this easily manipulated and clinically relevant model organism. Zebraﬁsh
permit mutational analyses of genetic function (gain or loss of function) and the rapid validation of human
variants as pathological mutations. In particular, neural degeneration can be characterized at genetic, cellular,
functional, and behavioral levels. Zebraﬁsh have been used to knock down or express mutations in zebraﬁsh
homologs of human genes and to directly express human genes bearing mutations related to
neurodegenerative disorders such as spinal muscular atrophy, ataxia, hereditary spastic paraplegia,
amyotrophic lateral sclerosis (ALS), epilepsy, Huntington's disease, Parkinson's disease, fronto-temporal
dementia, and Alzheimer's disease. More recently, we have been using zebraﬁsh to validate mutations of
synaptic genes discovered by large-scale genomic approaches in developmental disorders such as autism,
schizophrenia, and non-syndromic mental retardation. Advances in zebraﬁsh genetics such as multigenic
analyses and chemical genetics now offer a unique potential for disease research. Thus, zebraﬁsh hold much
promise for advancing the functional genomics of human diseases, the understanding of the genetics and cell
biology of degenerative and developmental disorders, and the discovery of therapeutics. This article is part of
a Special Issue entitled Zebraﬁsh Models of Neurological Diseases.raﬁsh Models of Neurological
nd Cell Biology, Université de
H3C 3J7, Canada. Tel.: +1 514
u).
l rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Zebraﬁsh are used as a model for a wide variety of human diseases,
including cancer, cardiovascular disorders, angiogenesis, hemophilia,
osteoporosis, diseases of muscle, kidney and liver, and, last but not the
least, disorders of the central nervous system. In recent years,
zebraﬁsh have been used to study neurodegenerative disorders.
Herewe review zebraﬁshmodels of CNS diseaseswith an emphasis on
studies of degenerative neurological diseases. We also discuss our
recent efforts in extending these approaches to psychiatric disorders
of development. Although unlikely to yield accurate models for
complex psychiatric disorders, genetic insights from studies of
zebraﬁsh are pertinent in helping to identify relevant molecular and
cellular mechanisms of human pathology and, at this level, promise
insight to the development of therapeutics. In particular, the in vivo
biological validation of variants identiﬁed in human genetic and
genomic studies provides an important step in deﬁning the
pathological nature of mutations.Apart from being a vertebrate with common organs and tissues
such as a brain and spinal cord with conserved organization, the
attractiveness of zebraﬁsh as a model lies in its biology and genetics.
Zebraﬁsh have large clutches of externally fertilized and transparent
eggs, which develop rapidly and in synchrony, with neurogenesis
starting around 10 h post-fertilization (hpf), synaptogenesis and the
ﬁrst behaviors around 18 hpf and hatching around 52 hpf. Within
1 day of development, many pertinent features of the CNS appear and
can be studied in relatively simple populations of identiﬁable neurons.
For example, the spinal cord is divided into 30 somites each
containing fewer than a dozen cell types that form relatively simple
circuits. The rapid development of the zebraﬁsh embryo allows for the
study of embryonic-lethal mutations as larvae can survive on their
yolk for up to a week, allowing studies of gene expression and
function throughout early developmental stages.
In addition to its advantageous biology, the second major
advantage of the zebraﬁsh as a model is the simplicity and
effectiveness of manipulating gene expression for cell biological
observations in living embryos with relevance to human pathology.
The zebraﬁsh genome is sequenced and, although not completely
annotated, over 80% of gene structures are available and show a high
degree of synteny (nearest neighboring genes on the chromosomes)
across vertebrate species as well as 50–80% homology with most
human sequences. Homologs for most human genes can be identiﬁed
in silico and, as described below, can bemanipulated by gain- and loss-
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homolog in zebraﬁsh is complicated by the fact that a large number
of genes are duplicated. This phenomenon is explained by whole
genome duplication that occurred during evolution [1]. The amino
acid identity compared to the human gene is always higher for one of
the two genes duplicated, indicating that the duplication appeared
before the species divergence. Therefore, when a gene is knocked
down, it is important to consider that the duplicated gene can
compensate for the loss of function of the targeted homolog. Also, the
function could be partitioned between the two genes or simply lost for
one of the genes. Comparative sequence analysis allows identifying
the zebraﬁsh homolog of a human gene. Three major genome
browsers, NCBI (www.ncbi.nlm.gov), Ensembl (www.ensembl.org)
and UCSC (/genome.ucsc.edu/), can be use to search homologous gene
sequences. In many cases, the homologous gene predictions can be
found directly from either HomolGene (NCBI) or Orthologue Prediction
(Ensembl). We have found that about half of the hundred or so human
synaptic genes on chromosome X (described later) have a predicted
ﬁsh ortholog, compared to ~30% in Drosophila and Caenorhabditis
elegans using the same databases. If the homologous gene is not
annotated or if the transcript prediction is not complete, a BLAST
search using nucleotide or protein sequence against the whole
genome assemblies (especially scaffolds based on BAC sequencing)
can allow the identiﬁcation of homologous genes. TargetP and SignalP
algorithms (www.cbs.dtu.dk/services/) can be used for signal peptide
and cleavage site prediction. An additional phylogenetic analysis and
multiple alignments of protein sequences (Clustal W) help to conﬁrm
the orthology. The syntenic regions can also be compared using Multi
Contig View (Ensembl). For additional information, the Sanger
Institute (www.sanger.ac.uk) has excellent resources about zebraﬁsh
sequence analysis. The sequence identity between zebraﬁsh genes
and their human homologs is higher for ubiquitously expressed genes
than for highly speciﬁc genes such as some synaptic genes. The
divergence is mainly found in domains important for membrane
targeting as signal peptides and often in intracellular domains that
contain signaling motifs. Nonetheless, in general, the exon/intron
boundaries and regulatory sequences as well as many other types of
functional domains are evolutionarily conserved between the species.
As a simple startingpoint, the zebraﬁshhomologs canbe targeted for
knockdown by injection of selective anti-sense morpholino oligonu-
cleotides (AMOs) [2]. ZFIN (zﬁn.org) has the principal database about
AMO gene knockdown and phenotype. The parameters to consider in
AMO design are the same as that for any oligonucleotide molecule: CG
content, stem and loop structure, and the oligo length [3]. Gene-Tools
Inc. (see www.gene-tools.com) offers an AMO design service to the
researchers purchasing their morpholinos. We recommend always
checking if the AMO can bind to off-target sequences by doing a BLAST
against NCBI or Ensembl database. AMOs can be designed to target the
ATG start site to block translation initiation or they can be used to block
splice sites to produce truncated transcripts. The latter have the
advantage of sparing maternal transcripts and permit RT-PCR ampliﬁ-
cation and quantiﬁcation of the gene knockdown, which is particularly
useful when an antibody is unavailable. Further, the splice AMO can be
used to mimic splicing defects, nonsense or truncation mutations
related to disease. AMOs resist degradation by ribonucleases and are
stable for several days, and in our hands when adequately controlled,
they usually generate selective phenotypes (discussed below). Howev-
er, AMOs must be injected intracellularly as they are more of a
pharmacological than a genetic tool, although they aremore effective in
gene knockdown in zebraﬁsh than interfering RNAs. Intracellular
injection is feasible in the zebraﬁsh embryo during the ﬁrst 1–2 hpf as
the blastomeres are open to the yolk prior to the 4th cell division. Free-
hand injection into the yolk near the blastomere border (Fig. 1) allows
for the injection of a hundred eggs or so in 1–2 h, yielding a sufﬁcient
number of treated embryos to permit statistical analyses of phenotypes
and thus providing a genetic read-out often only 1 day later.Replacing targeted zebraﬁsh genes with human genes can for
many genes be done as simply as by injection of human mRNA
simultaneously with the AMO as the latter is designed to speciﬁcally
target the zebraﬁsh and not the human sequence. We suggest using
the zebraﬁsh homologous cDNA if your gene of interest has a highly
localized expression pattern like that of synaptic genes. Otherwise,
human, mouse, or rat cDNA can be used and easily obtained
commercially. NCBI gives the link to cDNA clones for certain genes.
The gene can be subcloned in expression vectors like pCS2 [4] or
pcGlobin [5] to synthesize the 5′-cappedmRNA that will be injected in
embryos. The pcGlobin vector has the advantage to have 5′UTR and 3′
UTR from Xenopus, and we also note that pcGlobin gives a better yield
of mRNA. The cDNA can be tagged to MYC, ﬂag, or HA epitopes to
follow the expression in ﬁsh. However, large DNA constructs such as
plasmids often yield chimeric expression patterns in limited numbers
of cells presumably as not all dividing progenitors retain the large
constructs. About half of the human genes we have tested permit
partial rescue of knockdown phenotypes, which then allows for
comparison between wild-type human mRNA and mRNA bearing
disease-related mutations. Thus, in the space of a few weeks, each
human variant can be validated in knockdown embryos once a clear
phenotype is recognized. Finally and as described below, recent
transgenic technologies permit the creation of stable, targeted (cell-
speciﬁc), and inducible lines for better spatially and temporally
controlled and more detailed analyses of transgenic function.2. Degenerative brain disorders
Degenerative disorders of the brain, including Alzheimer's, Par-
kinson's, andHuntington's diseases, are the ﬁrst neurogenetic diseases
to have been studied using zebraﬁsh [6,7]. Amyloid-beta plaques are
the strongest biological marker of Alzheimer's disease and the
production of amyloid-beta is regulated by the presenilins 1 and 2
(PS1, PS2). Surprisingly, wt zebraﬁsh zPS1 was found to promote
aberrant amyloid-beta42 secretion when expressed in HEK 293 cells,
like the abnormal secretion associatedwith humanPS1mutations, and
mutation of one residue in zPS1 abolished this activity [8]. Truncation
of zPS1 due to loss of exons 8 and 9 upon injection of splice acceptor
AMOs had a dominant-negative effect by increasing PS1 expression [9]
and possibly the expression of other Alzheimer's-related genes [10].
Zebraﬁsh zPS2 is expressed at later stages and is regulated by zPS1
[11,12], but its role in amyloidogenesis in zebraﬁsh is unclear.
Zebraﬁsh possess two homologues of amyloid precursor protein
(APP) with 63–66% homology to their human counterpart [13], and
their double knockdown causes a convergence–extension develop-
mental defect that is rescued by human APP mRNA but not by a
Swedish mutation related to Alzheimer's disease [14]. The zebraﬁsh
APPs possess a functional gamma-secretase complex to produce
amyloid-beta [15] and inhibition of gamma-secretase [16] or knock-
down of Pen-2 [17], anothermember of the presinilin complex, blocks
Notch signaling to produce a severe neurogenic phenotype. Early
studies also examined the tau protein in zebraﬁsh as tau is present in
human neuroﬁbrillary tangles, mutations of tau are implicated in
dementia and tau may also contribute to Alzheimer's disease. The
zebraﬁsh studies have shown that expression of human tau (driven
transiently upon injection of a construct with a neural-speciﬁc variant
of the GATA2 promoter) results by 2 days in disruption of cytoskeletal
structure, tau trafﬁcking, and hyperphosphorylated ﬁbrillar tau
staining [18]. More recently, stable transgenic zebraﬁsh expressing
mutated P301L human tau and a ﬂuorescent reporter (driven pan-
neuronally from the HuC promoter) have permitted in vivo imaging of
defective axonal growth, tau hyperphosphorylation, and the screening
of novel therapeutic molecules [19]. These recent developments with
zebraﬁsh tau and amyloid open the possibility of further screens for
novel therapeutics that, e.g., decrease the hyperphosphorylation of tau
Fig. 1. Rescue of knockdown phenotypes by human mRNA allows for the validation of disease-related variants.
337E. Kabashi et al. / Biochimica et Biophysica Acta 1812 (2011) 335–345in HuC transgenics [19] or amyloid-beta load in amyloid transgenics
[20,21].
Research into Parkinson's disease has also used zebraﬁsh as a
model [22]. Zebraﬁsh embryos treated with MPTP, a neurodegener-
ative chemical that reproduces some of the effects of idiopathic
Parkinson's disease in mammalian models, demonstrated a loss of
dopaminergic neurons, which could be rescued using the monoamine
oxidase-B inhibitor deprenyl [23–25]. Half a dozen genes have been
identiﬁed in Parkinson's disease [26], and several of these have been
studied to date in zebraﬁsh. For example, in zebraﬁsh, the mRNA for
the ubiquitin processing gene UCH-L1 was detected by 1 day in the
ventral region of the midbrain and hindbrain and in the ventral
diencephalon where it was co-expressed with markers of dopami-
nergic neurons [27]. The zebraﬁsh DJ-1 protein has high (N80%)
homology with human and mouse DJ-1 (of unknown function) and is
expressed throughout the body [28]. Knockdown of DJ-1 in the
zebraﬁsh did not affect the number of dopaminergic neurons, but
zebraﬁsh embryos were more susceptible to oxidative stress and had
elevated SOD1 levels, while simultaneous knockdown of DJ-1 and p53
caused dopaminergic neuronal loss. Recently zebraﬁsh Parkin,
another ubiquitin processing gene, was identiﬁed (62% homology
with human PARKIN) and AMO abrogation of its activity leads to a
signiﬁcant decrease in the number of ascending dopaminergic
neurons in the posterior tuberculum, which is homologous to the
substantia nigra in humans [29]. Screens for compounds promoting
(like MPTP) or preventing (such as caffeine) the Parkinsonian
phenotype in zebraﬁsh [30] should now be facilitated by the
availability of an enhancer trap line expressing GFP from the vesicular
monoamine transporter 2 promoter [31].
In zebraﬁsh, the huntingtin (Htt) gene implicated in Huntington's
disease has a predicted 70% identity with the human protein [32] and
its knockdown disrupts a number of features [33] and causes massive
neuronal apoptosis due to reduced BDNF expression by 1 day of
development but not earlier [34]. It was recently observed that
injecting mRNA coding for the N-terminal fragment of Htt with
different length polyQ repeats led to developmental abnormalities
and apoptosis in the embryos as early as 1 day later [35]. Embryos
expressing a Q102 mRNA [35] or a Q56 plasmid [36] developed
inclusions in the cytoplasm. These Huntington's disease models are
being used to screen for novel therapeutics that could preventaggregate formation and clearance, such as anti-prion compounds
[35], or embryonic death, such as blockers of autophagy [37].
Another CNS disorder that has been studied recently using
zebraﬁsh is epilepsy [38] as clonus-like seizures are induced by
convulsant agents [39–42], which has permitted forwardmutagenesis
screens and the isolation of seizure-resistant mutants [43]. Zebraﬁsh
are now being used to screen for compounds that suppress seizures
[44]. Furthermore, injection of mRNA with a mutation of the human
PRICKLE1 gene implicated in epilepsy disrupts normal function when
overexpressed in zebraﬁsh [45], demonstrating the usefulness of
zebraﬁsh for validating mutations of human genes causing brain
disorders.
Our group has recently collaborated on the discovery of the
MEDNIK syndrome, a rare and severe autosomal recessive neurocu-
taneous disorder manifested by mental retardation, enteropathy,
deafness, neuropathy, ichthyosis, and keratodermia that is often lethal
[46,47]. Affected individuals bear an A to Gmutation in acceptor splice
site of exon 3 of the AP1S1 gene, which leads to a premature stop
codon (Fig. 2A [47]). The AP1S1 gene encodes the small subunit σ1A of
the ﬁrst (AP-1) of four ubiquitous clathrin adaptor proteins [48–51].
Each one of the adaptor protein complexes is assembled from four
subunits, and the σ subunit, the one affected in the MEDNIK
syndrome, is part of the AP complex core and is suggested to
contribute to its stabilization. Also, together with the μ subunit, the σ
subunit is possibly involved in protein cargo selection [50,51]. To
demonstrate that themutation in the human AP1S1 gene indeed alters
the biological function of this gene and underlies the MEDNIK
syndrome, we knocked down the function of the homologous Ap1s1
gene in zebraﬁsh. The zebraﬁsh Ap1s1 protein shares 91% identity
with the human protein. To inhibit zebraﬁsh Ap1s1mRNA translation,
two types of AMOs were designed (Fig. 2A [47]). The ﬁrst AMO
targeted the N-terminal, while the second AMO targeted the acceptor
splice site of intron 2 (Fig. 2A), imitating the mutation found in
MEDNIK patients. Both AMOs caused similar, severe morphological
and behavioral deﬁcits. The 48 hpf KD larva was smaller and had
reduced pigmentation compared to thewild-type (WT) larva. Further,
blocking Ap1s1 translation caused disorganized skin formation in
general, particularly affecting ﬁn morphology (Fig. 2B; for further
information on the epithelial disorders, see Ref. [47]). In addition to
the morphological deﬁcits, the 48 hpf KD larva responded abnormally
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compromised touch response of the KD larva could be attributed to
a massive reduction (by half) in the spinal neuron population,
speciﬁcally due to a loss in the interneuron population. The speciﬁcity
of the AMO effect was further conﬁrmed both byWestern blotting and
immunolabeling analysis (Fig. 2C and D). Most importantly, we could
rescue the knockdown phenotype by co-injecting the AMO with
human AP1S1 wild-type mRNA (Fig. 2B and D), which is not targeted
by the Ap1s1 AMO. In contrast, co-injection of AMO with mutated
human AP1S1mRNAmissing exon 3 (Fig. 2A) failed to rescue the skin
and behavioral deﬁcits, suggesting loss of function of this truncated
form of protein (Fig. 2C) and conﬁrming the pathogenic nature of the
mutation found in MEDNIK patients. Further, co-injection of AMO and
an additional human AP1S1mRNA isoform found in MEDNIK patients,
containing a cryptic splice acceptor site located 9 bp downstream ofFig. 2. Evaluating a mutation found in human AP1S1 gene (MEDNIK syndrome) using zebra
found inMEDNIK patients. An A to Gmutation in the acceptor splice site of exon 3 resulted in
splice site located 9 bp downstream of the start of the 3rd exon resulted in mRNA lacking 9 b
splice site of the zebraﬁsh ap1s1 gene is indicated in green. The inset on the right depicts th
which is mutated in MEDNIK patients. (B) Ap1s1 knockdown (KD) in zebraﬁsh using morph
resulted in a similar characteristic morphological phenotype (48 h post-fertilization), which
mRNA lacking 9 bp (rescue+−9 bp HmRNA), but not by the mutated human mRNA missi
proteins: normal protein containing 55AA (WT, black); truncated protein containing 19AA (
splicing (blue). Western blot analysis of Ap1s1 proteins from human (left) and zebraﬁsh (r
knockdown (KD) zebraﬁsh larva. To normalize the Western blot analysis, proteins extra
WT=wild type. (D) Localization of Ap1s1 in skin cells of zebraﬁsh wholemounts is illustra
well-deﬁned perinuclear ring can be nicely observed in both normal (WT) and rescued larva
in knockdown (KD) larvae (modiﬁed from Ref. [47]).the start of the 3rd exon, rescued the phenotype (Fig. 2A). The latter
result suggests that the predicted in frame protein, lacking only 3
amino acids (Fig. 2C), is functional andmay explain the viability of the
MEDNIK patients. However, the low expression level of the alterna-
tively spliced RNA (~10%) is insufﬁcient to sustain normal develop-
ment and function, further emphasizing the importance of AP1S1 in
normal development. Our in vivo zebraﬁsh study of Ap1s1 function
revealed its importance for appropriate neurogenesis and skin
development. Accordingly, we could speculate that MEDNIK, a novel
neurocutaneous syndrome, is caused by impaired development of
various neural networks in the spinal cord and in the brain, explaining
the multifunctional human deﬁcits such as ataxia, peripheral
neuropathy, and mental retardation, which are concomitant with a
perturbation in epithelial cell development in the skin and in the
digestive system.We speculate that these generalized effects of AP1S1ﬁsh. (A) An illustration of the human AP1S1 gene to show the location of the mutation
skipping of this exon and led to a premature stop codon. The use of an alternative cryptic
p. The location of the two different morpholinos targeting either ATG or exon 3 acceptor
e clathrin adaptor protein 1 (AP-1) and its 4 subunits. It is the small subunit σ1 (red),
olino oligo nucleotides targeting the N-terminal or the splice site (splice site, intron 2)
is rescued by co-injection of the wild-type human AP1S1 (rescue+WT HmRNA) or the
ng exon 3 (rescue+−exon3HmRNA). (C) Illustration of the predicated human AP1S1
red), the result of skipping exon 3; and a protein missing 3AA, a result of the alternative
ight) to show that Ap1s1 protein is hardly expressed in MEDNIK patients and in ap1s1
cted from WT, KD, and CTRL larvae were incubated with anti-actin. CTRL=control,
ted using anti-Ap1s1 antibody immunoﬂuorescence. Cell membrane (polygonal) and a
e (rescue+WTHmRNA), whereas only a residual and diffuse staining could be observed
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protein sorting.
3. Degenerative spinal cord disorders
Zebraﬁsh have also been proven to be particularly effective as a
model for motor dysfunction [52]. Our group has worked extensively
on motor neuron diseases, including the most common of these
disorders, amyotrophic lateral sclerosis (ALS). The advantage of
studying motor neuron diseases in zebraﬁsh consists in the rapid
development of the spinal cord and allowing analysis of motor neuron
branching patterns as early as 24 hpf. In addition, responses to touch
and swimming can be monitored following hatching around 48 hpf
[53]. SOD1 (ALS1) is known to cause ALS in 10–20% of familial ALS
cases mainly through an autosomal dominant toxic gain of function
and has 70% amino acid identity to the zebraﬁsh homologue.
Overexpression of mutant SOD1 in zebraﬁsh leads to short motor
axons with premature branching [54]. Interestingly, several other
genes implicated in motoneuron degeneration show a similar
phenotype when tested in zebraﬁsh. Alsin (ALS2) is the gene mutated
in juvenile ALS through autosomal recessive mode of action, which
leads in most cases to protein truncation. Corresponding to this, in
zebraﬁsh embryos, knockdown of Alsin (61% homology) by AMO
causes shortening of motor axons and also loss of neurons in the
spinal cord [55]. ELP3 was identiﬁed through association studies
performed in ALS patients and in a Drosophila screen for genes
important for neuronal survival [56]. Knockdown of this gene (ELP3)
in zebraﬁsh caused increased branching and shortened motor axons
[56]. Recently, TDP-43 was found enriched in inclusion bodies from
spinal cord autopsy tissue obtained from ALS patients [57]. Moreover,
about 30 mutations have been identiﬁed in a considerable number of
ALS patients, suggesting that this protein plays an important role in
disease pathogenesis [58,59]. The zebraﬁsh ztardbp gene product
(TDP-43) has 73% homology to the human protein. Knockdown of
TDP-43 (tardbp) in zebraﬁsh embryos led to motor neuron branching
and motility deﬁcits (Fig. 3). This AMO phenotype was rescued by co-
expressing human wild-type (WT) TDP-43 (which is not targeted by
the AMO) (Fig. 3). However, three ALS-related mutations of human
TDP-43 identiﬁed in both in SALS and FALS cases (A315T, G348C,
A382T) failed to rescue these phenotypes, indicating that these
mutants are pathogenic (Fig. 3). A similar phenotype was observed
when mutant (but not wt) TDP-43 was overexpressed, with the
G348C mutation being the most penetrant (Fig. 3). These results
indicate that TDP-43 mutations cause motor defects, suggesting that
both a loss as well as a gain of function may be involved in the
molecular mechanism of pathogenesis [125]. Finally, it is interesting
to note that a number of groups generated ALS2 knockout mice yet
failed to observe motor deﬁcits associated with motor neuron
degeneration and concluded that ALS2 was not an important gene
for ALS [55,60]. However, the ﬁrst three exons of ALS2 were left intact
in these mice. We found that the motor phenotype in zebraﬁsh upon
ALS2 KD could be partially rescued upon overexpression of the
alternative transcript of the ﬁrst three exons of ALS2, indicating that
complete disruption could in fact be pathogenic in ALS [55]. This
nicely illustrates the usefulness of zebraﬁsh knockdown models for
more complete disruption of gene function in some circumstances.
Zebraﬁsh have been also widely used to study the functional role
of genemutations in anothermotor neuron disease, hereditary spastic
paraplegia (HSP). Over 30 loci are known for this disorder, and at least
20 genes have been identiﬁed to cause spastic paraplegia [61]. Our
group identiﬁed missense variants in the KIAA0196 gene at the SPG8
locus and validated these mutations using the zebraﬁsh model (87%
homology to the human protein) [62]. Knockdown of the zebraﬁsh
homolog of KIAA0196 gene caused a curly-tail phenotype coupled
with shorter motor axons. This phenotype could be partially rescued
by the human WT KIAA0196 but not the two mutants identiﬁed inHSP patients [62]. Recently, SLC33A1 was identiﬁed as the gene
responsible for SPG42 [63]. Knockdown of this gene in zebraﬁsh
embryos using AMO caused a curly-tail phenotype and defective axon
outgrowth from the spinal cord [63]. Finally, knockdown of spastin
(SPG4) caused widespread defects in neuronal connectivity and
extensive CNS-speciﬁc apoptosis [64].
Spinal muscular atrophy (SMA) is an autosomally recessive motor
neuron disorder caused by mutations in the survival motor neuron
gene (SMN1). In a series of publications, Beattie's laboratory has
demonstrated that knockdown of the SMN1 in zebraﬁsh embryos
(49% homology to human protein) causes motor axon outgrowth and
pathﬁnding defects in early development [52,65]. Further, in a series
of elegant rescue experiments, this group was able to show that a
conserved region in exon 7 of the SMN1 gene (QNQKE) is critical for
axonal outgrowth and that the plastin 3 (PLS3) may be important for
axonal outgrowth since overexpression of plastin 3 rescued the
phenotype caused by SMN1 knockdown [66,67]. Finally, transgenic
expression of homozygous deletion found in SMA patients that leads
to truncated SMN1 protein as well as knocking out the Smn1 gene in
zebraﬁsh caused deﬁcits in the neuromuscular junction formation and
death at the larval stage [68].
4. Developmental disorders
Although this developmental model is proving useful in the
study of late-onset degenerative diseases, zebraﬁsh are just starting
to be used in the study of developmental brain diseases. Interesting
speculations have been made on the potential of zebraﬁsh for
modeling developmental psychiatric disorders such as autism [69],
but the lag in advancing these models is perhaps because the
clinical phenotypes are so subtle and speciﬁc to humans suffering
from disorders such as autism, schizophrenia, non-syndromic
mental retardation, and others that zebraﬁsh may appear as a
doubtful model. So far (and very recently), the only genes linked to
schizophrenia to be studied in zebraﬁsh using AMO methods are
DISC1 and NRG1 [70]. The receptor tyrosine kinase Met has been
implicated in cerebellar development and autism, and knockdown
of either Met alone or both of its Hgf ligands (two genes in
zebraﬁsh) together using ATG or splice junction AMOs results in
abnormal cerebellar and facial motoneuron development [71].
However, neither the human homologs of these genes nor their
disease-related mutations have been tested in zebraﬁsh. Our new
ongoing genomics approach, based on large-scale re-sequencing of
human synaptic genes in patients suffering from some of these
disorders, is identifying mutations that can be validated, if not
exactly modeled, in zebraﬁsh.
As a part of our “Synapse to Disease” project, we are using a
combination of AMO knockdown and gene overexpression to
functionally validate novel synaptic gene mutations identiﬁed in
large cohorts of patients with autism, schizophrenia, or non-
syndromic mental retardation. Hundreds of synaptic genes were
selected based on published studies and databases. Many genes were
chosen because they are X-linked [72] as there are many more
affected males than females in autism [73]. Other genes that were
selected are those of the glutamate receptor complex because of their
association to neurodevelopmental diseases [74]. So far, the exonic
regions of over 400 genes have been sequenced, and 15 de novo
mutations (present in the patients and not their parents) were
genetically validated (manuscript submitted). We have identiﬁed
deleterious rare de novo mutations in Shank3, IL1RAPL1, NRXN1, and
KIF17 genes, and all of these genes have orthologs in zebraﬁsh. We
have identiﬁed a de novo mutation in the Shank3 gene in a patient
with autism [75] as Shank3 deletions or duplications were previously
identiﬁed in patients with autism [76]. Shank3 encodes a scaffolding
protein found in excitatory synapses directly opposite to the pre-
synaptic active zone. The Shank proteins link ionotropic and
Fig. 3.Motor phenotype of gain and loss of function of TDP-43 in zebraﬁsh. (A) A schematic representation of TDP-43 protein showing the functional domains, localization of FLAG
(3 kDa) and myc tags (12 kDa), and sites where the G348C mutation found in ALS patients was introduced by site-directed mutagenesis. (B) Locomotor phenotype. Zebraﬁsh
embryos develop a touch-evoked escape response as seen when embryos are injected with WT human TDP-43 RNA. Expression of TDP-43 G348C RNA causes a deﬁciency in the
touch-evoked response. A similar phenotype is observed when the zf tdp-43 expressionwas knocked down using a speciﬁc AMO. This phenotype was rescued with expression ofWT
but not G348C RNA. (C) Motor axonal deﬁcits. The behavioral (motor) phenotype was selectively associated with a shortening of the axon and premature branching in motor
neurons (see G348C TDP-43 and tdp-43AMO) (modiﬁed from Kabashi et al., accepted at Hum. Mol. Genet.).
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cytoskeleton to regulate the structural organization of dentritic
spines. The splice mutation identiﬁed in the Shank3 gene would
result in a truncated protein lacking the Homer, Cortactin, and SAM
domains important for spine induction and dentritic targeting [77].
Zebraﬁsh have two Shank3 homologous genes (shank3a and shank3b).
The identity to human protein is overall 65% and 62% for shank3a and
shank3b, respectively, but when we compare every individual
functional domain to the human one, the amino acids identity reach
80% and is over 90% for the PDZ domain. The phenotype of Shank3
knockdown zebraﬁsh was not reported in the literature yet, and we
observed major motility deﬁcits that could be rescued by the rat
mRNA but not by some of the mutations [126].
We also found de novo mutations in IL1RAPL1 in autistic patients
[78]. IL1RAPL1 and 2 are plasma membrane proteins that belong to a
class of the interleukin-1 receptor family characterized by a 150-aa C-
terminal domain that interacts with Neuronal Calcium Sensor-1 (NCS-
1) [79,80]. A recent study from [81] used IL1RAPL1-deﬁcient mouse to
show that IL1RAPL1 controls inhibitory network during cerebellar
development. In one patient, a de novo frameshift mutation in
IL1RAPL1 causes a premature stop of the translation (I367fs) resulting
in a truncated protein, lacking the intracellular TIR domain and the C-
terminal domain interacting with NCS-1 [78]. Moreover, a large
deletion of exons 3 to 7 of IL1RAPL1 in three brothers with autism
and/or non-syndromic mental retardation was also identiﬁed in ourstudy. Mutations resulting in deletion of the TIR and the C-terminal
domains were previously identiﬁed in patients with non-syndromic
mental retardation [82,83], suggesting that those domains are
important to the protein function. Two genes encode IL1RAPL1 in
zebraﬁsh (il1rapl1a and il1rapl1b) and share 69% and 75% identity,
respectively, with human protein. The divergence is mainly in the
signal peptide (il1rapl1a: 42%, b: 47%). Recently, a study using
zebraﬁsh il1rapl1a showed that the mRNA is constantly expressed
during early embryonic development, indicating that it is maternally
provided [84]. In this study, they also showed that knockdown of the
other gene, il1rapl1b, using an ATG AMO caused a selective loss of
synaptic endings in olfactory neurons and that il1rapl1b C terminus
and TIR domains regulate the synaptic vesicles accumulation and
morphological remodeling of axon terminals during synapse forma-
tion [84]. These observations suggest that il1rapl1b may be essential
for synapse formation and indicate how a loss-of-function IL1RAPL1
mutant could affect brain neurodevelopment and its possible
association to autism and non-syndromic mental retardation. To
determine more speciﬁcally the function of IL1RAPL1 in the context of
schizophrenia, we knocked down the expression of zebraﬁsh il1rapl1a
with an ATG AMO and observed a severe phenotype with incomplete
development of the embryo, which could not be rescued by human
mRNA. These preliminary (unpublished) results indicate that
IL1RAPL1 plays an important function during early embryonic
development. Further work, such as with splice junction AMOs that
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required in order to develop a pathogenic validation.
Neurexins are predominantly pre-synaptic cell-adhesion mole-
cules. They can induce pre-synaptic differentiation by interactingwith
neuroligins. There are three neurexin genes (NRXN1, 2, and 3), each of
which encodes twomajor variants (alpha and beta). Only NRXN1 gene
was shown to be disrupted using CNV analysis in autism [85,86]. More
recently, NRXN1 gene has been involved in CNV found in SCZ patients
[87,88]. We have identiﬁed an insertion of 4 bp predicted to cause a
frameshift with a premature stop affecting the two major variants
alpha and beta of NRXN1 in SCZ patient. The protein is predicted to
miss the transmembrane and intracellular domains. Two orthologs of
NRXN1 have been identiﬁed in zebraﬁsh (Nrxn1a and 1b) with an
identity to the human protein over 70%. The greatest variability is
found in the signal peptide (Nrxn1a, 27%; 1b 32%). An expression
analysis showed that all three Nrxn genes are expressed during
zebraﬁsh embryonic development and some speciﬁc isoforms of
Nrxn1a expressed at different stage of the development [89]. These
results indicate the potential for developing zebraﬁsh models of
neurexin mutations. However, the fact that there exist thousands of
isoforms of Nrxn1 and the amino acids of the signal peptide are
divergent could make the functional validation in zebraﬁsh more
challenging.
Kinesin 17 (KIF17) is a member of the kinesin superfamily
containing a motor domain for ATP hydrolysis. KIF17 binds to the
scafolding Mint1 to transport the NMDA receptor subunit 2B (NR2B)
to the dendrites along microtubules [90,91]. In addition, the K+
channel Kv4.2, a major regulator of dendritic excitability, is also
transported to the dentrites by KIF17 [92]. In mice, overexpression of
Kif17 enhances spatial and working memory [93]. The expression of
KIF17was shown to be altered in amousemodels for Down syndrome
(trisomy 21) leading to learning deﬁcit [94]. We have identiﬁed a
nonsense mutation resulting in a protein that lacks the tail domain in
a SCZ patient. This domain was shown to interact with Mint1
following its phosphorylation by CaMKII [95]. One orthologous
sequence was identiﬁed in zebraﬁsh with an identity of 61% compare
to the human amino acids. The divergence wasmainly observed in the
motifs important for cargo binding. The zebraﬁsh KIF17 is widely
expressed in the nervous system and retina [96]. By using low doses
splicing AMO, this group demonstrates that KIF17 is essential for
vertebrate photoreceptor development and seems to have little effect
on the global zebraﬁsh development. At higher doses of either an ATG
or a splice junction AMO that micked the effect of the de novo
nonsense truncation mutation in schizophrenia, we observed a
characteristic dose-dependent morphological trait with stunted,
curly embryos [127]. This validates that the nonsense mutation is a
loss-of-function pathogenic effect.
Together, these results with several zebraﬁsh developmental
genes indicate the potential usefulness of this model for validating
brain disease mutations, but clearly each gene requires its own set of
carefully designed experiments. Whereas some human genes can be
more difﬁcult to study in zebraﬁsh, with others, one can observe
faithful disease phenotypes that can be characterized in detail such as
for AP1S1 in MEDNIK and ALS2 in ALS and thus provide novel insights
to these disorders.We have observed some knockdown phenotypes in
zebraﬁsh that are not as obvious in knockout mice, which may reﬂect
a lower degree of compensation in zebraﬁsh, perhaps because their
reproductive biology is based more on the quantity of offspring rather
than necessarily on the quality of developmental compensation.
5. Future directions
Several approaches have the potential of further advancing
zebraﬁsh models of human CNS disorders and making them uniquely
useful, in particular targeted expression, multigenic analysis and
chemical genetics.5.1. Targeted expression
Most of the approaches taken to date to express foreign genes in
zebraﬁsh are based on injection of mRNA for transient expression
throughout the embryo. This simple approach is valid for ubiqui-
tously and early expressed genes such as AP1S1, SOD1, TARDBP and
members of the ubiquination and beta-secretase complexes dis-
cussed above. However, mRNA injection risks expressing genes
ectopically, such as in the case of synaptic genes, and is usually only
efﬁcient at embryonic stages, prior to mRNA degradation that occurs
within a few days. The latter thus limits the time course for
phenotypic analysis, which is particularly problematic for studies of
neurogeneration in (often) adult-onset human diseases. More
speciﬁc expression patterns can be achieved by stable transgenesis
using the efﬁcient Tol2 transposon system [97], but this is best suited
for generating long-term models (rather than for preliminary or
large-scale screens) as it is a slower process that requires the raising
of founder ﬁsh and their out-crossing to verify stable and speciﬁc
transgenic lines. A number of promoters are available for neural-
speciﬁc transgenic expression. For example, the α-tubulin promoter
[98] was the ﬁrst used to drive pan-neuronal expression and, as
described above, the HuC promoter expressed in post-mitotic
neurons [19] and a neural-speciﬁc variant of the GATA2 promoter
[18] are also effective at early stages. More selective subsets of
neurons can be targeted using more restrictive promoters such as the
dopaminergic-speciﬁc vesicular monoamine transporter 2 promoter
[31]. In the spinal cord, which is an important region for studies of
motor dysfunction and synaptic transmission, the developmentally
conserved transcriptional code [99] has permitted the generation of
transgenic lines for selective types of neurons. These include
motoneurons: HB9 [100], Isl-1 [101], commissural neurons: Evx1
[102], mostly glycinergic neurons: Pax2.1 [103]; vGlyT2 [104], mostly
glutamatergic neurons: Alx/Vsx2 [105], as well as sensory neurons:
Ngn1 [106] and oligodendrocytes: Nkx2.2a [107], olig2 [108] and
sox10 [109].
However, these stable transgenic models also have their limita-
tions, and here, we consider three major ones that can be at least
partially avoided depending on necessity: ectopic expression, toxic
expression, and genetic background. Although promoter-based stable
transgenic lines confer more selective expression patterns, rarely do
they perfectly recapitulate the natural expression patterns as often
only subsets of enhancer elements are used in generating the
transgenic constructs. Indeed, this is a limitation of the lack of a
knock-in technology in zebraﬁsh, requiring the integration of novel
constructs in a wild-type background (considered below). However,
perfectly faithful expression patterns are not always essential as
expression in incomplete or expanded subsets of neurons can be
useful to study. An approach that provides a more accurate expression
pattern is the use of bacterial artiﬁcial chromosomes (BACs), such as
with the amyloid line mentioned above [21]. In principle (although
we are unaware of its practice with zebraﬁsh), humanized models
could be generated based on transgenesis with human BACs, as is
commonly done with mice. However, vertebrate genes can be
hundreds of kilobases in size and are not always completely contained
within single BACs. As an alternative, pufferﬁsh (Takifugu rubripes)
BACs can be used as the intergenic regions are much smaller, an
approach we have taken in generating an Evx1 transgenic line [102],
although even in this case less than 80% of the neurons labeled by a
selective antibody to evx1 also expressed GFP, indicating that not all
evx1 cells transgenically express GFP.
A second issue in considering stable transgenic lines is toxicity, as
many of the transgenes bearing disease-related mutations can be
embryonic-lethal. A simple approach is to drive expression from a
heat shock promoter [110], although this may lose in generalized
spatial expression what it gains in restricted temporal activation. A
powerful alternative is the use of combinatorial expression systems,
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binary system popular for invertebrate genetics, both of which have
found applications in zebraﬁsh [111,112]. Examples are the Evx1-Gal4
[102] and HuC-Gal4 [19] lines described earlier. The latter drives
transcription in both directions from the UAS in order to express two
constructs simultaneoulsy, such as a gene of interest (in this case
human P301L tau) and a reporter (dsRed) in the same cells. Another
technique for expressingmore than one gene from the same construct
is to use the self-cleaving viral 2A peptide as a linker between the
genes of interest [113].
A ﬁnal concern is the creation of transgenic lines in a genetic
background containing the endogenous gene as (in the absence of
knock-in technology) this results in the addition of another gene. One
possibility that is rarely used is to create a transgenic in a knockout
background. In principle, this can be done if mutants have been
isolated in screens for related phenotypes or by TILLING (Targeted
Induced Local Lesions in Genomes) [114] available through a new
consortium (see https://webapps.fhcrc.org/science/tilling/). A new
technology is the targeted lesioning of genes by zinc ﬁnger nucleases
(ZFN) [115], although this is a complex and expensive technology that
at the moment is beyond the reach of small laboratories. Preliminary
success in targeting genes in zebraﬁsh is encouraging, and the
possibility to use homologous recombination, rather than non-
homologous end joining, to repair ZFN-induced double-strand breaks
may permit the development of a knock-in approach for zebraﬁsh
[116]. Much works remain to be done before this enticing possibility
becomes practical, but nonetheless, a number of transgenic
approaches are now available for reﬁned studies of gene expression
and function in zebraﬁsh, including human genes bearing disease-
related mutations.
5.2. Multigenic analysis
Although highly penetrant mutations of single genes are often
implicated in CNS disorders, such as the majority considered in this
review, most diseases are multigenic in nature, requiring multiple
weakly penetrating mutations in predisposing genetic backgrounds in
order to produce the disease. Existing genetic models most easily
address single gene mutations (or rather have focused on these
simple cases), but clearly, the future of these models lies in their
ability to provide insights to the nature of genetic interactions in
disease. The zebraﬁsh may prove to be particularly amenable to
multigenic analysis by a combination of the approaches described
above. The use of two or even three AMOs is a simple solution once
each AMO is validated. For example, in the context of Parkinson's
disease, simultaneous knockdown of DJ-1 and p53was found to cause
dopaminergic neuronal loss [28] and knockdown of both Hgf ligands
was necessary to induce Met-related cerebellar defects [71]. Also,
photoactivatable caged AMOs can be used to release these at speciﬁc
time points [117]. This approach seems promising, but unfortunately,
caged AMOs are not available commercially yet. Another major
limitation of the AMO is the necessity to inject in embryo at 1 or 2 cells
stage. An interesting alternative would be to use the vivo-AMOs that
allow making gene knockdown and splice modiﬁcation in adult
animals. The vivo-AMOs are modiﬁed AMO able to enter cells by
endocytosis. They could be conjugated with a dendrimeric octagua-
nidine (Gene Tools) or a cell-penetrating peptide linked to phosphor-
odiamidate (PPMO) (AVI BioPharma Inc.). Vivo-AMOs were shown to
be effective in mice [118,119], and they are currently tested in adult
zebraﬁsh [3].
By performing AMO injections in mutants or transgenics, either
stable or inducible, it should in principle be possible to readily test
several genes simultaneously or in different combinations, bestowing
zebraﬁsh with a polyvalence that is difﬁcult to envisage for other
models such as mice. In the case of mutant and transgenic back-
grounds, comparative microarray screening [120] becomes feasible,particularly as multiple conditions (e.g., different mutant alleles)
permit internal veriﬁcation and comparison of the array results. A
pertinent example is the recent microarray analysis [121] of three
alleles of the neurogenic mindbomb mutant affecting Notch signaling
for which each allele affected the expression of hundreds of genes but
less than 100 were commonly affected. Thus, zebraﬁsh have a unique
potential for rapidly analyzing multiple genes and dissecting complex
genetic pathways.
5.3. Chemical genetics
While zebraﬁsh retain advantages for studying the genetics,
biology, and pathobiology of disease genes of interest, they also
have the major advantage of being the only vertebrate model
amenable to large chemical genetic screens [122]. Small chemical
libraries of over 10,000 molecules, including approved drugs and
randomly synthesized organic molecules of unknown function, have
been screened in zebraﬁsh models of cancer [123] and cardiovascular
disorders [124], and some of these are in clinical testing. With the
numerous models of brain diseases being developed in zebraﬁsh, this
approach holds much potential for drug discovery. This is particularly
attractive in zebraﬁsh as functional chemical genetic screens in vivo
with living embryos offer the potential of discovering therapeutics
without prior knowledge or need for rational screening designs. Thus,
zebraﬁsh are a unique model ranging from molecular genetic
validation to drug discovery with important applications on the
horizon for brain diseases, including many complex and untreatable
disorders.
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